EVE Evolva Holding SA

Evolva publishes timeline of the Reverse Stock Split

Evolva Holding SA / Key word(s): AGMEGM
Evolva publishes timeline of the Reverse Stock Split

24.04.2023 / 07:00 CET/CEST


 

Reinach, 24 April 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, today communicates on the timeline of the reverse stock split of 250:1 which was approved by shareholders at the Annual General Meeting on 18 April 2023 by a large majority:

  • 25 April 2023: Last trading day of old shares on SIX Swiss Exchange
  • 26 April 2023: First trading day of new shares on SIX Swiss Exchange (ex-date)

The reverse split of shares may result in fractions of new registered shares for the individual shareholder. This is the case if shareholders hold an amount of Evolva shares that is not divisible by 250 or a multiple thereof after the 25 April 2023. Fractions in new shares are rounded down to the next whole number and shareholders will receive an equivalent cash compensation for their fractions.

Further information regarding the reverse split can be found in the Q&A on Evolva's website ().

 

Important dates

24 August 2023 Half-year 2023 results 

 

 

Contact

Doris Rudischhauser

Head of Investor Relations and Corporate Communications

8

 

 

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to wellness, health and sustainability. Find out more at and connect with us on .

For Evolva multimedia content, please visit: .

 

 

Disclaimer
This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.             
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

 



End of Media Release


Language: English
Company: Evolva Holding SA
Duggingerstrasse 23
4153 Reinach
Switzerland
Phone: 0
Internet:
ISIN: CH0021218067
Valor: 2121806
Listed: SIX Swiss Exchange
EQS News ID: 1614491

 
End of News EQS News Service

1614491  24.04.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1614491&application_name=news&site_id=research_pool
EN
24/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evolva Holding SA

 PRESS RELEASE

Shareholders of Evolva Holding SA in liquidation approve BoD proposals...

Evolva Holding SA / Key word(s): AGMEGM Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected 12.04.2024 / 19:10 CET/CEST PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR   Shareholders of Evolva Holding SA in liquidation approve proposals put forward by the Board of Directors at Annual General Meeting; of the three agenda items put forward by Nice & Green, revocation of the liquidation and the delisting were also approved whereas introduc...

 PRESS RELEASE

Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG...

Evolva Holding SA / Key word(s): Takeover Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 28.12.2023 / 17:45 CET/CEST PRESS RELEASE   Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023 Reinach, Switzerland, 28 December 2023 — Following the approval on 21 December 2023 by the shareholders of Evolva Holding AG (SIX: EVE) of the sale of Evolva AG to Danstar Ferment AG, a Swiss affiliate of Lallemand Inc., the parties have successfully closed the transaction on 28 December 2023. Evolva Holding S...

 PRESS RELEASE

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss sub...

Evolva Holding SA / Key word(s): AGMEGM Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting 21.12.2023 / 17:45 CET/CEST PRESS RELEASE   Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting Reinach, 21 December 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved all the proposals put forward by the Board of Directors at today’s extraordinary general meeting (EGM). The sharehol...

 PRESS RELEASE

Evolva and Breko broaden partnership by signing agreement for the excl...

Evolva Holding SA / Key word(s): Agreement Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam 14.11.2023 / 07:00 CET/CEST PRESS RELEASE   Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTMResveratrol in Germany, Austria, Thailand and Vietnam Reinach, 14 November 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and Breko GmbH, Bremen, Germany (“Breko”), a leading supplier of p...

 PRESS RELEASE

Evolva shareholders approve increase of the conditional capital and up...

Evolva Holding SA / Key word(s): AGMEGM Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 24.08.2023 / 20:00 CET/CEST PRESS RELEASE   Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023 Reinach, 24 August 2023 — The shareholders of Evolva Holding SA (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, approved the proposals put forward by the Board of Direct...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch